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PROPHYLAXIS AGAINST DEEP-VEIN 
THROMBOSIS AND FATAL PULMONARY 
EMBOLISM IN KNEE ARTHROPLASTIES:
A COST-EFFECTIVENESS STUDY
Nerurkar J, Wade WE, Martin BC
The University of Georgia College of Pharmacy, Athens, GA, USA
OBJECTIVE: This study seeks to determine the costs and
effectiveness of warfarin, ardeparin, enoxaparin, and no-
prophylaxis for patients undergoing knee arthroplasty.
METHODS: A decision-analytic model was developed
using TreeAge software to compare the three treatment
strategies and a no-prophylaxis option. The effectiveness
measure was deaths prevented for a simulated cohort of
10,000 patients undergoing knee arthroplasty. Costs were
valued in U.S. dollars using a payer’s perspective and
costs and probabilities of events were obtained from the
published literature. RESULTS: All three treatment strat-
egies were cost saving and more effective than the no pro-
phylaxis option. Enoxaparin had the lowest expected
cost of $3,242 per patient and prevented 198 deaths for
the cohort of 10,000 persons. Warfarin was dominated
by enoxaparin and ardeparin was the most effective op-
tion and had a marginal cost-effectiveness ratio of $207,342
per death avoided. Results of the sensitivity analysis will
be presented. CONCLUSION: All three treatments are
cost saving and more effective than no prophylaxis indi-
cating that prophylaxis is preferred to the do nothing
strategy. Warfarin was dominated by enoxaparin and
should not be considered a first line anticoagulant to pre-
vent DVT in this patient population. Ardeparin was the
most effective option that had a marginal cost-effective-
ness ratio above many societal willingness to pay thresh-
olds and may not be considered a desirable use of health
care resources. The robustness of these findings will be
explored using sensitivity analysis.
PCV10
RETROSPECTIVE MEDICAL RECORD REVIEW 
TO DETERMINE THE “AT GOAL” PATIENTS 
WITH HYPERTENSION AND/OR DYSLIPIDEMIA
Gunnarsson P1, Livengood K2, Lytken Larsen M3, Pettersson 
S4, Claeys MJ5, Norstrom F6, Saldeen Nilehn K7, Beys J8
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Sweden; 7Department of Internal Medicine, Sahlgrenska University 
Hospital, Gothenburg, Sweden; 8St. Maarten Ziekenhuis,
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OBJECTIVE: To generate data about treatment patterns
for patients with hypertension and/or dyslipidemia and
to identify the number achieving a treatment goal accord-
ing to international guidelines. The data collected will
also be used to validate a new software program that the
Outcomes Research department at Pfizer has developed.
METHODS: Six clinics/doctors in three European coun-
tries (Belgium, Denmark, and Sweden) participated in
this retrospective medical record review. For each patient
visit, the available data from the previous 1–2 years was
collected. Data collected included blood pressure mea-
surements, lipid profiles, glucose levels, HbA1c, co-mor-
bidities, and medications. Guidelines used in the analysis
were: Hypertension—1999 WHO-ISH guidelines for the
management of hypertension; Hyperlipidemia—Recom-
mendations of the Second Joint Task Force of European
and other Societies on Coronary Prevention. RESULTS:
Reviewing each patient’s last visit, 33 of 189 were at goal
for hypertension or 17%. For lipids, 42 of 179 (32%)
were at goal. 50% of patients diagnosed with diabetes
had HbA1c below 7% at the last visit and 65% of them
were at goal for lipids, but only 14% for hypertension.
CONCLUSION: The number of patients found to be “at
goal” in this study is far from being optimal, but it is sim-
ilar to numbers seen in the literature. The software was
found to function as expected by utilizing only the data
that doctors routinely collect in their practice. The “at
goal” information is valuable, because it allows health
care providers to track over time one of the factor’s that
will be (and is being) used to measure the quality of the
care they are providing. HMOs in the US can use the in-
formation gathered to create reports for NCQA and HE-
DIS and in the UK the new cardiovascular NSF standards
have been incorporated into the software.
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DETERMINANTS OF COSTS AND RESOURCE 
UTILIZATION ASSOCIATED WITH OPEN 
HEART SURGERY
Sokolovic E1, Schmidlin D2, Schmid E2, Ruef C3, Szucs T1
1Department of Medical Economics, University Hospital, 
Zurich, Switzerland; 2Institute for Anesthesiology, University 
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OBJECTIVE: This study sought to determine the corre-
lates of in-hospital costs for patients undergoing open-
heart surgery at the 962 bed University Hospital in Zurich.
METHODS: We performed a retrospective analysis of all
heart surgery patients referred to University Hospital who
were covered by a fixed fee (29 500 SFr) arrangement in
1998, except those who had heart transplantation. We an-
alyzed the prospectively evaluated preoperative (age, BMI,
clinical characteristics, preoperative scores, history of pre-
vious heart surgery), intraoperative (operation time,
anesthesia time, extracorporal circulation time, intubation
hours) respectively postoperative (APACHE II, SAPS II
Scores, infection, rethoracotomy) factors. RESULTS: In
total 242 patients were hospitalized in 1998 under this
fixed fee arrangement. The treatment of 69 patients (29%)
caused costs higher than 40 000 SFr. Median cost per pa-
